Glioblastoma multiforme (also known as a grade IV astrocytoma), is a rapidly progressing

tumor of the central nervous system that forms from the supportive tissue (glial cells) in 

the brain and, less frequently, the spinal cord. GBM accounts for more than 60% of the 

brain tumors diagnosed in the human adults and yet it there is currently no cure available 

for these patients. In the US alone, this represents over 12,000 new patients diagnosed 

each year with GBM and the current prognosis for these patients is a 14 months life 

expectancy (with currently available standard of care) and a 98% death rate 5 years after 

diagnosis, designating this type of cancer an Orphan Disease by the FDA. The lack of a cure 

for GBM makes this disease the third leading cause of cancer-related mortality in males 18-

54 years old and the fourth leading cause in females 18-34 years. GBM also accounts for 

approximately 25% of brain tumors diagnosed in children and represents the leading cause 

of cancer-related mortality in children less than 18 years old. Thus there is an urgent need 

for novel therapeutics that will safely treat and cure patients diagnosed with GBM.